U.S. FDA Says Limited Availability Of Mounjaro, Injection, 10 mg/.5 ml Through Early March 2024; Limited Availability Of Mounjaro, Injection, 15 mg/.5 ml Through Early March 2024; Limited Availability Of Mounjaro, Injection, 12.5 mg/.5 ml Through Early March 2024
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA announced that there will be limited availability of Mounjaro injections in dosages of 10 mg/.5 ml, 15 mg/.5 ml, and 12.5 mg/.5 ml through early March 2024.
March 05, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly's Mounjaro injections will have limited availability in various dosages until early March 2024 as per the FDA announcement.
The limited availability of Mounjaro injections could potentially impact Eli Lilly's sales and revenue in the short term, as Mounjaro is a significant product for the company. The announcement by the FDA directly affects the supply chain and availability of the product, likely leading to a negative perception among investors and possibly affecting the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100